Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
230
mi
from 43215
Stevensville, MI
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
230
mi
from 43215
Stevensville, MI
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
320
mi
from 43215
High Point, NC
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
320
mi
from 43215
High Point, NC
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
488
mi
from 43215
Wilmington, NC
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
488
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
129
mi
from 43215
Cleveland, OH
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
113
mi
from 43215
Mogadore, OH
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
113
mi
from 43215
Mogadore, OH
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
99
mi
from 43215
Wadsworth, OH
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
99
mi
from 43215
Wadsworth, OH
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
525
mi
from 43215
Mount Pleasant, SC
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
525
mi
from 43215
Mount Pleasant, SC
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
237
mi
from 43215
Bristol, TN
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
237
mi
from 43215
Bristol, TN
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
937
mi
from 43215
Fort Worth, TX
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1519
mi
from 43215
West Jordan, UT
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1519
mi
from 43215
West Jordan, UT
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
388
mi
from 43215
Williamsburg, VA
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
388
mi
from 43215
Williamsburg, VA
Click here to add this to my saved trials
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1912
mi
from 43215
Wenatchee, WA
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1912
mi
from 43215
Wenatchee, WA
Click here to add this to my saved trials
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
831
mi
from 43215
Tampa, FL
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
2006
mi
from 43215
Seattle, WA
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Status: Enrolling
Updated:  12/31/1969
Northern Virginia Pediatrics
mi
from 43215
Falls Church, VA
Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Status: Enrolling
Updated: 12/31/1969
Northern Virginia Pediatrics
mi
from 43215
Falls Church, VA
Click here to add this to my saved trials
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated:  12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated: 12/31/1969
Johnson County Clin-Trials
629
mi
from 43215
Lenexa, KA
Click here to add this to my saved trials
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
620
mi
from 43215
Kansas City, MO
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
620
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
1519
mi
from 43215
West Jordan, UT
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
1519
mi
from 43215
West Jordan, UT
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2112
mi
from 43215
Daly City, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2112
mi
from 43215
Daly City, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2078
mi
from 43215
Fairfield, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2078
mi
from 43215
Fairfield, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2101
mi
from 43215
Redwood City, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2101
mi
from 43215
Redwood City, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2092
mi
from 43215
Vallejo, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2092
mi
from 43215
Vallejo, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2084
mi
from 43215
Walnut Creek, CA
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2084
mi
from 43215
Walnut Creek, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
4501
mi
from 43215
Honolulu, HI
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
4501
mi
from 43215
Honolulu, HI
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from 43215
Waianae, HI
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from 43215
Waianae, HI
Click here to add this to my saved trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
4504
mi
from 43215
Waipio, HI
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
4504
mi
from 43215
Waipio, HI
Click here to add this to my saved trials
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
A Randomized, Controlled, Evaluator-blinded, Multi-center Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety, and Tolerability in Patients With Complicated Intra-abdominal Infection
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from 43215
Somers Point, NJ
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
A Randomized, Controlled, Evaluator-blinded, Multi-center Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety, and Tolerability in Patients With Complicated Intra-abdominal Infection
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from 43215
Somers Point, NJ
Click here to add this to my saved trials
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women.
Status: Enrolling
Updated:  12/31/1969
Restore Clinical Research
mi
from 43215
Cary, NC
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women.
Status: Enrolling
Updated: 12/31/1969
Restore Clinical Research
mi
from 43215
Cary, NC
Click here to add this to my saved trials
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
797
mi
from 43215
Orlando, FL
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
797
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
992
mi
from 43215
Miami, FL
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
Status: Enrolling
Updated:  12/31/1969
UMass Memorial Medical Center - university campus
604
mi
from 43215
Worcester, MA
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
Status: Enrolling
Updated: 12/31/1969
UMass Memorial Medical Center - university campus
604
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1655
mi
from 43215
Chandler, AZ
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1655
mi
from 43215
Chandler, AZ
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1972
mi
from 43215
Paramount, CA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1972
mi
from 43215
Paramount, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2040
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2111
mi
from 43215
Santa Rosa, CA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2111
mi
from 43215
Santa Rosa, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1165
mi
from 43215
Longmont, CO
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1165
mi
from 43215
Longmont, CO
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
423
mi
from 43215
Marietta, GA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
423
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
448
mi
from 43215
Stockbridge, GA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
448
mi
from 43215
Stockbridge, GA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
413
mi
from 43215
Woodstock, GA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
413
mi
from 43215
Woodstock, GA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
780
mi
from 43215
Wichita, KA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
780
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
156
mi
from 43215
Lexington, KY
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
156
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
166
mi
from 43215
Nicholasville, KY
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
166
mi
from 43215
Nicholasville, KY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
331
mi
from 43215
Columbia, MD
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
331
mi
from 43215
Columbia, MD
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
230
mi
from 43215
Stevensville, MI
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
230
mi
from 43215
Stevensville, MI
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
397
mi
from 43215
Saint Louis, MO
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
414
mi
from 43215
Syracuse, NY
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
414
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2052
mi
from 43215
Albany, OR
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2052
mi
from 43215
Albany, OR
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
158
mi
from 43215
Carnegie, PA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
158
mi
from 43215
Carnegie, PA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
214
mi
from 43215
Erie, PA
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
214
mi
from 43215
Erie, PA
Click here to add this to my saved trials